Consensus Egetis Therapeutics AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
4.57 ^SEK	-1.40%		-16.91%	-18.10%

Jun. 20	Transcript : Egetis Therapeutics AB - Special Call
Jun. 19	Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	CI

3e063690e.iBvIkcb_o4TE6-tBrJNOfAWI6PxldDVi1OdPW8fuwig.sUOH4I2X--38hN4p66AvBUHPubkMIVsLnKkmFrWNkWbmeqKm8YnT9KqBgA~7029fcf7928ab1a23f91ea669497bd6f

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.57 SEK

Average target price

13.3 SEK

Spread / Average Target

+191.03%

High Price Target

18 SEK

Spread / Highest target

+293.87%

Low Price Target

6 SEK

Spread / Lowest Target

+31.29%

Trading Rating

Investor Rating

ESG Refinitiv